Fidelity Investments’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-907,057
Closed -$16.1M 4440
2018
Q3
$16.1M Buy
907,057
+14,827
+2% +$255K ﹤0.01% 1775
2018
Q2
$12.3M Buy
892,230
+489,099
+121% +$5.8M ﹤0.01% 1889
2018
Q1
$3.66M Sell
403,131
-1,698,584
-81% -$9.37M ﹤0.01% 2249
2017
Q4
$8.99M Sell
2,101,715
-342,377
-14% -$1.63M ﹤0.01% 1984
2017
Q3
$3.45M Sell
2,444,092
-1,096,111
-31% -$1.53M ﹤0.01% 2226
2017
Q2
$5.31M Buy
3,540,203
+31,168
+0.9% +$66.9K ﹤0.01% 2150
2017
Q1
$9.02M Buy
3,509,035
+24,625
+0.7% +$57K ﹤0.01% 2002
2016
Q4
$8.88M Buy
3,484,410
+23,670
+0.7% +$68K ﹤0.01% 2016
2016
Q3
$10.7M Sell
3,460,740
-17,972
-0.5% -$56K ﹤0.01% 1959
2016
Q2
$11.2M Sell
3,478,712
-112,287
-3% -$412K ﹤0.01% 1918
2016
Q1
$11.1M Buy
3,590,999
+15,404
+0.4% +$50.3K ﹤0.01% 1913
2015
Q4
$14.3M Sell
3,575,595
-3,320
-0.1% -$15.3K ﹤0.01% 1834
2015
Q3
$16.4M Sell
3,578,915
-240,958
-6% -$1.26M ﹤0.01% 1728
2015
Q2
$19.8M Sell
3,819,873
-1,101,850
-22% -$6.61M ﹤0.01% 1738
2015
Q1
$30.8M Sell
4,921,723
-82,192
-2% -$474K ﹤0.01% 1563
2014
Q4
$31.5M Sell
5,003,915
-105,008
-2% -$640K ﹤0.01% 1546
2014
Q3
$31.1M Sell
5,108,923
-295,649
-5% -$2.02M ﹤0.01% 1535
2014
Q2
$35.6M Sell
5,404,572
-693,720
-11% -$7.81M ﹤0.01% 1510
2014
Q1
$145M Buy
6,098,292
+2,557,977
+72% +$37.1M 0.02% 784
2013
Q4
$37.8M Buy
3,540,315
+323,500
+10% +$3.57M 0.01% 1449
2013
Q3
$42.9M Buy
3,216,815
+1,270,774
+65% +$20.1M 0.01% 1364
2013
Q2
$25.6M Buy
+1,946,041
New +$26.2M ﹤0.01% 1552

Other funds holding ECYT

Fidelity Investments's ECYT Position: Q4 2018 in Review

Fidelity Investments sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 907,057 shares — an estimated $16.1M sold.

Fidelity Investments first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $145M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Fidelity Investments reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Fidelity Investments sold 907,057 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $16.1M.
  • Fidelity Investments first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
  • Fidelity Investments's Endocyte, Inc. Common Stock position peaked at $145M in Q1 2014.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Fidelity Investments's 13F filing for Q4 2018, filed 13 Feb 2019.